Search review questions

Drop‐outs (12 to 14 weeks) · Adults with mental disorders in low‐ and middle‐income countries

Fasting blood glucose (12 to 14 weeks)(endpoint data) · Adults with mental disorders in low‐ and middle‐income countries

Fasting blood glucose (12 to 14 weeks)(change from baseline data) · Adults with mental disorders in low‐ and middle‐income countries

BMI (12 to 14 weeks) · Adults with mental disorders in low‐ and middle‐income countries

Successful discontinuation rate · participants with depressive or anxiety disorders

Relapse (as defined by study authors) (HR) · participants with depressive or anxiety disorders

Withdrawal symptoms · participants with depressive or anxiety disorders

Adverse events · participants with depressive or anxiety disorders

Depressive symptoms · participants with depressive or anxiety disorders

Anxiety symptoms · participants with depressive or anxiety disorders

Quality of life · participants with depressive or anxiety disorders

Social and occupational functioning · participants with depressive or anxiety disorders

Successful discontinuation rate: proportion (%) of participants who successfully stopped use of antidepressants at the end of the trial · participants with long‐term antidepressants for depressive disorders

Risk of relapse (as defined by study authors) (HR) · participants with long‐term antidepressants for depressive disorders

Withdrawal symptoms · participants with long‐term antidepressants for depressive disorders

Relapse (as defined by study authors) (HR) · participants with depressive or anxiety disorders

Adverse events · participants with long‐term antidepressants for depressive disorders

Depressive symptoms · participants with long‐term antidepressants for depressive disorders

Anxiety symptoms · participants with long‐term antidepressants for depressive disorders

Quality of life · participants with long‐term antidepressants for depressive disorders

Social and occupational functioning · participants with long‐term antidepressants for depressive disorders

Successful discontinuation rate: proportion (%) of participants who successfully stopped use of antidepressants at the end of the trial Defined as no antidepressant use during the preceding 6 months and absence of a depressive or anxiety disorder · participants with long‐term antidepressants for depressive or anxiety disorders

Relapse rate · participants with long‐term antidepressants for depressive or anxiety disorders

Withdrawal symptoms · participants with long‐term antidepressants for depressive or anxiety disorders

Adverse events · participants with long‐term antidepressants for depressive or anxiety disorders

Depressive symptoms · participants with long‐term antidepressants for depressive or anxiety disorders

Withdrawal symptoms · participants with depressive or anxiety disorders

Anxiety symptoms · participants with long‐term antidepressants for depressive or anxiety disorders

Quality of life · participants with long‐term antidepressants for depressive or anxiety disorders

Social and occupational functioning · participants with long‐term antidepressants for depressive or anxiety disorders

Adverse events · participants with depressive or anxiety disorders

Depressive symptoms · participants with depressive or anxiety disorders

Anxiety symptoms · participants with depressive or anxiety disorders

Quality of life · participants with depressive or anxiety disorders

Social and occupational functioning · participants with depressive or anxiety disorders

Successful discontinuation rate Studies without co‐intervention · participants with depressive or anxiety disorders

MST vs ECT ‐ symptom severity ‐ HAMD (high = poor; short term) · patients with schizophrenia

MST vs ECT ‐ cognitive function ‐ immediate memory (high = better; short term) · patients with schizophrenia

MST vs ECT ‐ cognitive function ‐ delayed memory (high = better; short term) · patients with schizophrenia

MST vs ECT ‐ suicides, suicide attempts, self‐harm · patients with schizophrenia

MST vs ECT ‐ quality of life · patients with schizophrenia

MST vs ECT ‐ social functioning · patients with schizophrenia

MST vs ECT ‐ dropout for any reason (short term) · patients with schizophrenia

MST vs ECT ‐ serious adverse events · patients with schizophrenia

MST vs ECT ‐ adverse events that led to discontinuation of treatment (short term) · patients with schizophrenia

Depression response (acute, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months

Depression remission (early phase, < 5 weeks) · women of any age, with PND up to 12 months

Depression severity ‐ mean EPDS score (early phase, < 5 weeks) · women of any age, with PND up to 12 months

Treatment acceptability ‐ dropouts (early phase, < 5 weeks) · women of any age, with PND up to 12 months

Child‐related outcomes · women of any age, with PND up to 12 months